|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-3
|
|
pubmed:abstractText |
Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for long-term use. Valganciclovir, which has an oral bioavailability of 60%, has proven to be useful for prophylaxis of CMV infection in high-risk SOT recipients and for treating retinitis in persons with acquired immunodeficiency syndrome.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:AguadoJosé MaríaJM,
pubmed-author:BorrellNúriaN,
pubmed-author:BouGermánG,
pubmed-author:CarratalàJordiJ,
pubmed-author:CerveraCarlosC,
pubmed-author:CisnerosJosé MiguelJM,
pubmed-author:Cuervas-MonsValentínV,
pubmed-author:GavaldàJoanJ,
pubmed-author:GurguíMercèM,
pubmed-author:LenOscarO,
pubmed-author:Martin-DávilaPilarP,
pubmed-author:MontejoMiguelM,
pubmed-author:MuñozPatriciaP,
pubmed-author:PahissaAlbertA,
pubmed-author:RESITRA,
pubmed-author:Torre-CisnerosJuliánJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
20-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18171208-Adolescent,
pubmed-meshheading:18171208-Adult,
pubmed-meshheading:18171208-Aged,
pubmed-meshheading:18171208-Antibiotic Prophylaxis,
pubmed-meshheading:18171208-Antiviral Agents,
pubmed-meshheading:18171208-Cohort Studies,
pubmed-meshheading:18171208-Cytomegalovirus Infections,
pubmed-meshheading:18171208-Drug Therapy, Combination,
pubmed-meshheading:18171208-Female,
pubmed-meshheading:18171208-Ganciclovir,
pubmed-meshheading:18171208-Humans,
pubmed-meshheading:18171208-Immunocompromised Host,
pubmed-meshheading:18171208-Male,
pubmed-meshheading:18171208-Middle Aged,
pubmed-meshheading:18171208-Postoperative Complications,
pubmed-meshheading:18171208-Prospective Studies,
pubmed-meshheading:18171208-Transplantation,
pubmed-meshheading:18171208-Transplantation Immunology
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
|
|
pubmed:affiliation |
Spanish Network for Research on Infection in Transplantation, Spain. olen@ir.vhebron.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
